Stockscreener 앱 받기
68.57
1.54%
-1.07
시간 외 거래:
68.57
전일 마감가:
$69.64
열려 있는:
$69.64
하루 거래량:
1.57M
Relative Volume:
0.97
시가총액:
$8.13B
수익:
$1.51B
순이익/손실:
$348.84M
주가수익비율:
24.66
EPS:
2.7805
순현금흐름:
$667.65M
1주 성능:
-2.74%
1개월 성능:
+2.16%
6개월 성능:
+4.26%
1년 성능:
+29.11%
1일 변동 폭
$68.18
$70.39
1주일 범위
$67.94
$72.25
52주 변동 폭
$51.06
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
68.57 | 8.45B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Halozyme (HALO) CLO reports RSU vesting and share withholding for taxes - Stock Titan
(HALO) Volatility Zones as Tactical Triggers - Stock Traders Daily
Halozyme Therapeutics Expects Proposed Rule to Have Little Impact on Royalties - marketscreener.com
Halozyme sees minimal impact from Medicare drug pricing rule - Investing.com
Halozyme sees minimal impact from Medicare drug pricing rule By Investing.com - Investing.com UK
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 - PR Newswire
HALOZYME THERAPEUTICS INC (HALO) Stock Chart - ChartMill
Halozyme Therapeutics (HALO) up 0.8% since last earnings report: Can it continue? - MSN
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance Singapore
Halozyme Therapeutics (HALO) CFO files Form 3 insider ownership statement - Stock Titan
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Uncovering a 17.29% Potential Upside with Strong Revenue Growth - DirectorsTalk Interviews
Natixis Advisors LLC Has $6.68 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Quick ratio of Halozyme Therapeutics, Inc. – XETR:RV7 - TradingView
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Data And Analyst Buy Reaffirmation - Sahm
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics, Inc. Income Statement – XETR:RV7 - TradingView
TD Asset Management Inc Lowers Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme licenses Hypercon technology to Oruka for psoriasis drug - Investing.com
Halozyme Therapeutics (HALO) Gains 2.76% as Shares Approach Key ResistanceMA Crossover - newsline.com
How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Yahoo Finance
Halozyme Therapeutics(HALO.US) Officer Sells US$3.37 Million in Common Stock - Moomoo
Halozyme CEO Helen Torley sells $3.37m in shares after exercising options By Investing.com - Investing.com South Africa
Halozyme Therapeutics Stock Gains 5.2% on Analyst Buy Rating and argenx Data NewsNews and Statistics - IndexBox
Halozyme CEO Helen Torley sells $3.37m in shares after exercising options - Investing.com
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today - Yahoo Finance
Halozyme (NASDAQ: HALO) CEO sells 50K shares after exercising 50K options - Stock Titan
Halozyme Therapeutics (NASDAQ:HALO) Trading Up 5.6%Here's What Happened - MarketBeat
Halozyme Therapeutics Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet
Benchmark reiterates Halozyme stock Buy rating on long-term potential - Investing.com
Benchmark reiterates Halozyme stock Buy rating on long-term potential By Investing.com - Investing.com Canada
Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E - ChartMill
Insider Sell Alert: Bernadette Connaughton Sells Shares of Haloz - GuruFocus
Insider Sell Alert: Bernadette Connaughton Sells Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus
Director at Halozyme (NASDAQ: HALO) sells shares under Rule 10b5-1 plan - Stock Titan
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a 26% Potential Upside for Investors - DirectorsTalk Interviews
Legal & General Group Plc Cuts Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme earnings up next: Can drug delivery platform sustain growth? By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (HALO) Holds Above Key Support as Selling Pressure EasesInstitutional Buy Signals - newsline.com
Halozyme to acquire Elektrofi, a biopharma focused on drug delivery - MSN
Halozyme Therapeutics Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Implied volatility surging for Halozyme Therapeutics stock options - MSN
Halozyme Therapeutics Q1 earnings call highlights - MSN
Implied Volatility Surging for Halozyme Therapeutics Stock Options - Yahoo Finance
Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a Promising 22.8% Potential Upside - DirectorsTalk Interviews
(HALO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
LSV Asset Management Has $87.56 Million Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Mizuho Markets Americas LLC Acquires 926,526 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO News | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Assessing Halozyme Therapeutics (HALO) Valuation After Recent Flat Share Price And Strong Longer Term Returns - Sahm
New GSK ENHANZE Deal and Bigger Buybacks Might Change The Case For Investing In Halozyme (HALO) - simplywall.st
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Jun 01 '26 |
Option Exercise |
12.07 |
20,000 |
241,400 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Jun 02 '26 |
Option Exercise |
12.07 |
20,000 |
241,400 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Jun 03 '26 |
Option Exercise |
12.07 |
10,000 |
120,700 |
777,780 |
| Torley Helen | PRESIDENT AND CEO |
Jun 01 '26 |
Sale |
67.58 |
20,000 |
1,351,610 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Jun 02 '26 |
Sale |
66.39 |
20,000 |
1,327,745 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Jun 03 '26 |
Sale |
69.07 |
10,000 |
690,653 |
767,780 |
| Connaughton Bernadette | Director |
Jun 01 '26 |
Sale |
66.21 |
1,625 |
107,591 |
43,669 |
2.60%
0.94%
자본화:
|
볼륨(24시간):